Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

1Bayer HealthCare Pharmaceuticals, Montville, NJ, USA; 2University Hospital Gasthuisberg/Leuven, Leuven, Belgium; 3San Martino Hospital, Genoa, Italy; 4Ospedale Niguarda Ca’ Granda, Milan, Italy; 5University Hospital, Pisa, Italy; 6CRLC Val d’Aurelle, Montpellier, France; 7St-Luc University Hospital, Brussels, Belgium; 8Robert Debre University Hospital, Reims, France; 9Institut Sainte-Catherine, Avignon, France; 10Catholic University of Sacred Heart, Rome, Italy; 11Centre Oscar Lambret, Lille, France; 12Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain; 13National Cancer Center Hospital East, Kashiwa, Japan; 14University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA; 15Ohio State University School of Medicine, James Cancer Hospital and Solove Research Institute, Columbus, OH, USA; 16Mayo Clinic, Rochester, MN, USA; 17Bayer Pharma AG, Berlin, Germany